Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's

Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's

Source: 
Fierce Pharma
snippet: 

Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother.

MorphoSys, partnered with the New Jersey drugmaker’s Janssen unit, said Tuesday that the drug giant had started up a phase 2/3 clinical trial program in Crohn’s disease, reaching for an indication that J&J immunology blockbuster Stelara bagged in 2016.